SCHEMBL1015626

SCHEMBL1015626

Cc1ccc(-c2ccc(F)cc2)cc1NC(=O)COCC(=O)Nc1ccc(Cl)cc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.53
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
SERPINE1 P05121 4/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
POLB P06746 1/20 0.48
G6PD P11413 1/20 0.48
MAPT P10636 2/20 0.48
KDM4E B2RXH2 2/20 0.47
GAA P10253 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
HSD17B10 Q99714 1/20 0.46
TP53 P04637 1/20 0.45
THRB P10828 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1016816 0.92 RXFP1 (0.46) RXFP1ALDH1A1LMNASERPINE1POLB
SCHEMBL1016253 0.91 RXFP1 (0.45) RXFP1ALDH1A1LMNASERPINE1POLB
SCHEMBL1015634 0.91 ALDH1A1 (0.53) RXFP1ALDH1A1LMNASMN1; SMN2POLB
SCHEMBL1015322 0.89 ALDH1A1 (0.54) RXFP1ALDH1A1LMNASERPINE1SMN1; SMN2
SCHEMBL1015691 0.88 ALDH1A1 (0.52) ALDH1A1LMNASERPINE1SMN1; SMN2POLB
SCHEMBL1014820 0.88 KDM4E (0.53) ALDH1A1LMNASERPINE1SMN1; SMN2POLB
SCHEMBL1015269 0.87 GRIK1 (0.52) SERPINE1SMN1; SMN2POLBG6PDMAPT
SCHEMBL1016283 0.87 KDM4E (0.52) RXFP1ALDH1A1SERPINE1MAPTKDM4E
SCHEMBL417503 0.86 MAPT (0.64) RXFP1ALDH1A1LMNASERPINE1SMN1; SMN2
SCHEMBL1015135 0.86 GRIK1 (0.51) SERPINE1SMN1; SMN2POLBG6PDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US claimed
EP-2990057-B1 PAI-1 INHIBITOR FOR USE IN ENHANCING THE ANTITUMOR EFFECT OF AN ANTITUMOR AGENT IN A PATIENT RENASCIENCE CO LTD (JP) 2019-03-20 EP disclosed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US disclosed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 RXFP1 1415/4885ALDH1A1 888/4885LMNA 525/4885
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 RXFP1 3001/4885ALDH1A1 273/4885LMNA 1331/4885
US-10092537-B2 Use for PAI-1 inhibitor SERPINE1, SERPINC1, SERPINB1 RXFP1 3510/4885ALDH1A1 177/4885LMNA 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.